Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120
mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria for ADHD